TerrAscend (TSNDF) Income from Non-Controlling Interests (2021 - 2026)
TerrAscend (TSNDF) posted quarterly Income from Non-Controlling Interests of $1.1 million for Q1 2026, down 18.89% year-over-year from $1.3 million in Q1 2025, and down 5.04% quarter-over-quarter from $1.1 million in Q4 2025.
TerrAscend (TSNDF) Income from Non-Controlling Interests (2021 - 2026) Analysis & Trends
TerrAscend (TSNDF) has reported Income from Non-Controlling Interests for 6 consecutive years, with $1.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Non-Controlling Interests fell 18.89% year-over-year to $1.1 million; the TTM figure through Mar 2026 stood at $4.7 million (down 30.17% YoY), while the FY2025 annual figure was $4.9 million, down 35.24% from the prior year.
- Income from Non-Controlling Interests declined to $1.1 million in Q1 2026 per TSNDF's latest filing, from $1.1 million in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at $2.3 million in Q4 2023 and bottomed at $351000.0 in Q1 2022.
- Historically, Income from Non-Controlling Interests has averaged $1.6 million across 5 years, with a median of $1.7 million in 2024.
- Annual changes were most pronounced in 2023 — Income from Non-Controlling Interests surged 522.79% — and 2025, when it slumped 40.93%.
- TerrAscend's Income from Non-Controlling Interests stood at $1.0 million in 2022, then surged by 124.66% to $2.3 million in 2023, then declined by 27.42% to $1.7 million in 2024, then slumped by 34.05% to $1.1 million in 2025, then dropped by 5.04% to $1.1 million in 2026.
- Business Quant data shows TSNDF's Income from Non-Controlling Interests at $1.1 million in Q1 2026, $1.1 million in Q4 2025, and $1.2 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.33 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 376,434.15 |
| 5 | United Therapeutics | 22.15 Bn | 19.48 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.74 Bn | 11.21 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | TerrAscend | 187.17 Mn | 145.05 Mn | 36.25 Mn | 1.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.11 Mn |
| Mar 31, 2026 | 1.06 Mn |
| Dec 31, 2025 | 1.11 Mn |
| Sep 30, 2025 | 1.21 Mn |
| Jun 30, 2025 | 1.28 Mn |
| Mar 31, 2025 | 1.30 Mn |
| Dec 31, 2024 | 1.69 Mn |
| Sep 30, 2024 | 1.73 Mn |
| Jun 30, 2024 | 1.94 Mn |
| Mar 31, 2024 | 2.20 Mn |
| Dec 31, 2023 | 2.32 Mn |
| Sep 30, 2023 | 2.16 Mn |
| Jun 30, 2023 | 2.14 Mn |
| Mar 31, 2023 | 2.19 Mn |
| Dec 31, 2022 | 1.03 Mn |
| Sep 30, 2022 | 2.23 Mn |
| Jun 30, 2022 | 945,000.00 |
| Mar 31, 2022 | 351,000.00 |
| Dec 31, 2021 | 556,000.00 |
| Sep 30, 2021 | 1.41 Mn |